Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.
about
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancyComparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovirSusceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovirInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene productFlow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.Clinical uses of cidofovir.Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless miceEvaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosidesPotent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Adenoviral disease in pediatric solid organ transplant recipients.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical StudiesConversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.Cidofovir Activity against Poxvirus Infections.Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.Disposition of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.Thiazolo[4,5-d]pyrimidines. Part II. Synthesis and anti-human cytomegalovirus activity in vitro of certain acyclonucleosides and acyclonucleotides derived from the guanine analogue 5-aminothiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione.Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis.Cidofovir in the treatment of cytomegalovirus (CMV) retinitis.Cidofovir in the treatment of cytomegaloviral disease.
P2860
Q27005614-4A91E4E6-1E19-4162-9E97-FACE0A5859ACQ28343171-6E390D24-D79B-4A4F-A377-6B7C86A4D7F7Q28353356-D286EAF7-F4B4-4558-8714-531B70698EA8Q28362995-9BA6305C-2FA7-4F14-B376-81F43FA0D40EQ28379289-8138D8E2-05B4-4802-AD2E-7DD4E1438C7BQ33661417-29B1715E-79E0-4894-8DFB-51BB7FAC942BQ33867391-E7117500-0D1F-4BF1-B233-E31D0B23E2EBQ34922842-9572C260-DE0B-4CF8-999D-93E49F6582EAQ35007525-3B0A2292-2E07-4A25-926F-0F2EF67BDEA2Q35124909-89D165D4-534A-4DD2-BE63-B535DDFBC065Q35126399-98915232-D3B3-40BA-8F73-D6037FE1465AQ35558801-1F94826C-853A-4157-A935-9FE1F95686EFQ36405590-EE7DF0E1-72E2-4264-92B6-92A0E8E759EAQ36407276-9AD7A719-8729-424B-9E5C-6C13041034C8Q37420102-4FE2F4FC-28DF-47EC-9B9E-6A4C25EEAEE8Q38530119-7332218F-508D-4135-BFAD-4CDAA6AE2F6DQ38614278-7B9DEC0D-82E6-4A05-B4A9-4DCBA7BBA5CCQ39474100-4855519F-C0FE-4697-B1D2-B50906860B05Q39556643-96941804-2A9B-45EF-9BA2-2051F036E1E5Q39558455-BFA15882-2488-457C-800C-6F25F7486B41Q40632749-6652A6CD-B731-446D-AF3A-99C9BB4FC2ADQ40860325-2E6F982C-089D-48A3-9996-65151E7C72DAQ40983979-FAF05D66-A92C-4E87-9BE2-CB7368E17C91Q42692480-9656EBEA-B724-48F7-B8B2-06166C981800Q43649096-5843B8AA-EA90-404C-8B7E-7E1CFA2890F8Q54115801-D51C3A3E-D5D7-4682-8222-FC779A029348
P2860
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@ast
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@en
type
label
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@ast
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@en
prefLabel
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@ast
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@en
P2093
P2860
P356
P1476
Anticytomegaloviral activity a ...... n and cytomegalovirus viruria.
@en
P2093
J A Kovacs
J F Manischewitz
K M Spooner
P E Fisher
R E Walker
P2860
P304
P356
10.1128/AAC.39.4.882
P407
P577
1995-04-01T00:00:00Z